Trial Profile

A Phase 2/3 Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zavegepant (Primary)
Indications Migraine; Migraine with aura; Migraine without aura
Focus Therapeutic Use
Sponsors Biohaven Pharmaceutical Holding Company; Pfizer

Most Recent Events

01 May 2024 Status changed from active, no longer recruiting to discontinued. (Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.)
20 Mar 2024 Planned End Date changed from 12 Mar 2024 to 20 Mar 2024.
20 Mar 2024 Planned primary completion date changed from 12 Mar 2024 to 20 Mar 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com